Kim McDonald, MD
Internal Medicine · Florissant, MONPI 1386636009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 28.1% of the total. Reporting peaked in 2019 at $1,652 and has fallen 91.4% since, to $142 in 2025. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$883
- Lilly USA, LLC$548
- Pfizer$510
- Astellas Pharma US Inc$342
- Sanofi-aventis U.S. LLC$276
- plus $1K from 21 others
Across 3 payments — averaging $66,815 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$200K
What the payments were for
- Food & beverage$5,203100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $1,466 |
| Novo Nordisk | 50 | $883 |
| Lilly USA, LLC | 20 | $548 |
| Pfizer | 20 | $510 |
| Astellas Pharma US Inc | 9 | $342 |
| Sanofi-aventis U.S. LLC | 16 | $276 |
| Arbor Pharmaceuticals, Inc. | 11 | $168 |
| Merck | 11 | $164 |
| Exact Sciences | 3 | $142 |
| Johnson & Johnson | 7 | $127 |
| Esperion Therapeutics, Inc. | 4 | $81 |
| Abbott | 4 | $68 |
| Amarin Pharma, Inc. | 5 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Rhodes Pharmaceuticals L.p. | 3 | $45 |
| AbbVie | 3 | $43 |
| Zyla Life Sciences, Inc. | 3 | $41 |
| Bayer | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Cranial Technologies, Inc | 1 | $14 |
| Optos, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,223 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $80,074 |
| TrulicityDulaglutide | 21 | $27,680 |
| EliquisApixaban | 28 | $26,086 |
| JanuviaSitagliptin Phosphate | 15 | $20,485 |
| MyrbetriqMirabegron | 13 | $16,023 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $11,124 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $8,340 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $4,438 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,629 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,666 |
| Amlodipine Besylate | 272 | $1,362 |
| Rosuvastatin Calcium | 170 | $1,154 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,152 |
| Nifedipine ErNifedipine | 63 | $1,088 |
| Celecoxib | 18 | $958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $883 | $80,07437 claims |
| Lilly USA, LLCTrulicity | $548 | $27,68021 claims |
| PfizerEliquis | $510 | $26,08628 claims |
| MerckJanuvia | $164 | $20,48515 claims |
| Astellas Pharma US IncMyrbetriq | $342 | $16,02313 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $276 | $11,12412 claims |
| AstraZenecaSymbicort | $1,466 | $2,62911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Florissant
- Timothy SmithSaint Peters$428K
- Craig DietzKansas City$226K
- Kevin SuttmoellerKansas City$198K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Dima DandachiColumbia$157K
- Justin SteinkampSaint Charles$139K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.